 | • レポートコード：MRC2303F0160 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、232ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に5,463.66百万ドルであった世界の自家幹細胞＆自家非幹細胞ベース治療薬市場規模が、2022年に6,256.31百万ドルになり、2027年まで年平均14.68%で成長して12,431.29百万ドルに拡大すると予測しています。本レポートでは、自家幹細胞＆自家非幹細胞ベース治療薬の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（自家非幹細胞、自家幹細胞）分析、用途別（がん、心血管疾患、神経変性疾患、整形外科疾患、その他）分析、エンドユーザー別（外来手術センター、病院、研究施設）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、主要企業として、Antria, Inc、Bioheart, Inc、Brainstorm Cell Therapeutics, Inc、Caladrius Biosciences Inc.、Castle Creek Biosciences Inc.、Cytori Therapeutics, Inc.、Dendreon Corporation、Fibrocell、Genesis Biopharma、Georgia Health Sciences University、Gilead Sciences Inc.、Neostem、Novartis AG、Opexa Therapeutics、Orgenesis、Pharmicell Co. Ltdなどの企業情報を含んでいます。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の自家幹細胞＆自家非幹細胞ベース治療薬市場規模：種類別 - 自家非幹細胞治療薬の市場規模 - 自家幹細胞治療薬の市場規模 ・世界の自家幹細胞＆自家非幹細胞ベース治療薬市場規模：用途別 - がんにおける市場規模 - 心血管疾患における市場規模 - 神経変性疾患における市場規模 - 整形外科疾患における市場規模 - その他用途における市場規模 ・世界の自家幹細胞＆自家非幹細胞ベース治療薬市場規模：エンドユーザー別 - 外来手術センターにおける市場規模 - 病院における市場規模 - 研究施設における市場規模 ・世界の自家幹細胞＆自家非幹細胞ベース治療薬市場規模：地域別 - 南北アメリカの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 アメリカの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 カナダの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ブラジルの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ... - アジア太平洋の自家幹細胞＆自家非幹細胞ベース治療薬市場規模 日本の自家幹細胞＆自家非幹細胞ベース治療薬市場規模 中国の自家幹細胞＆自家非幹細胞ベース治療薬市場規模 インドの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 韓国の自家幹細胞＆自家非幹細胞ベース治療薬市場規模 台湾の自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ... -ヨーロッパ/中東/アフリカの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 イギリスの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ドイツの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 フランスの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ロシアの自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ... -その他地域の自家幹細胞＆自家非幹細胞ベース治療薬市場規模 ・競争状況 ・企業情報 |
The Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market size was estimated at USD 5,463.66 million in 2021 and expected to reach USD 6,256.31 million in 2022, and is projected to grow at a CAGR 14.68% to reach USD 12,431.29 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Autologous Stem Cell & Non-Stem Cell Based Therapies to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Autologous Non-Stem Cells and Autologous Stem Cells.
Based on Application, the market was studied across Cancer, Cardiovascular Disease, Neurodegenerative Disorders, Orthopedic Diseases, and Others.
Based on End-User, the market was studied across Ambulatory Surgical Centers, Hospitals, and Research Facilities.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Autologous Stem Cell & Non-Stem Cell Based Therapies market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Autologous Stem Cell & Non-Stem Cell Based Therapies Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market, including Antria, Inc, Bioheart, Inc, Brainstorm Cell Therapeutics, Inc, Caladrius Biosciences Inc., Castle Creek Biosciences Inc., Cytori Therapeutics, Inc., Dendreon Corporation, Fibrocell, Genesis Biopharma, Georgia Health Sciences University, Gilead Sciences Inc., Neostem, Novartis AG, Opexa Therapeutics, Orgenesis, Pharmicell Co. Ltd, Regeneus, Regenexx, Tengion, TiGenix, U.S. Stem Cell, Inc., and VIRxSYS Corporation.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
4. What is the competitive strategic window for opportunities in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
5. What are the technology trends and regulatory frameworks in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
6. What is the market share of the leading vendors in the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
7. What modes and strategic moves are considered suitable for entering the Global Autologous Stem Cell & Non-Stem Cell Based Therapies Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rise in the prevalence of cancer and diabetes
5.1.1.2. Increased in demand due to ability to treat a large number of infectious diseases
5.1.1.3. Advantage of intensive therapy for older patients
5.1.2. Restraints
5.1.2.1. Lack of a significant therapeutic graft-versus-tumor effect
5.1.2.2. Chances of cells contamination with bacteria
5.1.3. Opportunities
5.1.3.1. Rise in investment for extensive research and development
5.1.3.2. Advances in treating various diseases neurodegenerative diseases and macular degeneration
5.1.4. Challenges
5.1.4.1. Risks and complications associated with the therapy
5.2. Cumulative Impact of COVID-19
6. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by Type
6.1. Introduction
6.2. Autologous Non-Stem Cells
6.3. Autologous Stem Cells
7. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by Application
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular Disease
7.4. Neurodegenerative Disorders
7.5. Orthopedic Diseases
7.6. Others
8. Autologous Stem Cell & Non-Stem Cell Based Therapies Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgical Centers
8.3. Hospitals
8.4. Research Facilities
9. Americas Autologous Stem Cell & Non-Stem Cell Based Therapies Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Autologous Stem Cell & Non-Stem Cell Based Therapies Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Autologous Stem Cell & Non-Stem Cell Based Therapies Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Antria, Inc
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Bioheart, Inc
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Brainstorm Cell Therapeutics, Inc
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. Caladrius Biosciences Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Castle Creek Biosciences Inc.
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Cytori Therapeutics, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Dendreon Corporation
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Fibrocell
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Genesis Biopharma
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Georgia Health Sciences University
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Gilead Sciences Inc.
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Neostem
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Novartis AG
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Opexa Therapeutics
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Orgenesis
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Pharmicell Co. Ltd
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Regeneus
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Regenexx
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Tengion
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. TiGenix
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. U.S. Stem Cell, Inc.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. VIRxSYS Corporation
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing